• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma USA 2023: Digital Therapeutics and Pharma

Article

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Tracey Dodenhoff, CEO of Medly Therapeutics, discusses her company's heart failure app and why pharma should consider prescription digital therapeutics among their offerings.

Recent Videos
Related Content
Kirsten Jacobs

The Lifespan of Mature Drugs in 2025: Q&A with Kirsten Jacobs

Mike Hollan
December 18th 2024
Article

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs.

Seeking More Value, Less Cost

Seeking More Value, Less Cost

Michael Christel
December 17th 2024
Article

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Dealmaking Dormant No More

Dealmaking Dormant No More

Mike Hollan
December 17th 2024
Article

Unleashed demand over the past year characterizes the M&A picture in pharma.

DTC's New Era of Engagement

DTC's New Era of Engagement

Don Tracy, Associate Editor
December 16th 2024
Article

How alternative direct-to-consumer models are changing the landscape for patient access.

The Recipe for Relief: Overcoming Industry Pain Points

The Recipe for Relief: Overcoming Industry Pain Points

Diane Petrone
December 13th 2024
Article

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

Pharma Forecasting: Key Markets Investors Can’t Ignore

Pharma Forecasting: Key Markets Investors Can’t Ignore

Na Wei;Joerg Tritschler;Martin Slusarczyk, PhD
December 13th 2024
Article

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.